Early-stage Drug Discovery

JSBio, a prominent brand in Asia, is a leading provider of serum-free cell culture media. Our comprehensive product portfolio covers a wide spectrum of cell lines, with a strong focus on mainstream ones like CHO, 293, insect cells, and BHK .These media are extensively applied across core biopharmaceutical ...

Thousand Oaks Biopharmaceutical (TOBio), as a CDMO specializing in the large molecule sector, offers an integrated suite of CMC solutions from candidate molecules through clinical and commercial manufacturing. Operating with the philosophy of an "innovator's drug development perspective," the core technica...

SHANGHAI, Oct. 13, 2025 /PRNewswire/ -- Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person (QP) and formally received a QP Declaration. This milestone certifies that the company's quality management system and commercial production capability in the field of antibody-drug conjugates (ADCs) comply with EU Good Manufacturing Practice (GMP) standards, positioning Thousand Oaks Biologics Shanghai as one of the few CDMOs in China offering end-to-end international ADC services.

Thousand Oaks Biologics Inc. (TOBio), a premier Integrated CMC Solution Provider, focuses on comprehensive solutions for large - scale, compliant biopharmaceutical production. Its business covers three main segments: Biopharmaceutical CDMO, Cell Culture Medium, and Early - Stage Research Services. Its products and technical services find extensive applications in the production of recombinant proteins, antibody - based drugs, human and veterinary vaccines, and cell therapy products.